ストックスクリーナーアプリを入手
1.05
0.00%
0.00
アフターアワーズ：
1.05
前日終値:
$1.05
開ける：
$1.05
24時間の取引高:
66,179
Relative Volume:
0.13
時価総額：
$24.83M
収益：
-
当期純損益:
$-14.33M
株価収益率:
-1.5909
EPS:
-0.66
ネットキャッシュフロー:
$-13.21M
1週間 パフォーマンス:
-1.41%
1か月 パフォーマンス:
+0.96%
6か月 パフォーマンス:
+2.94%
1年 パフォーマンス:
-22.22%
1日の値動き範囲:
$1.0286
$1.0686
1週間の範囲:
$1.0286
$1.16
52週間の値動き範囲:
$0.8101
$2.10
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
ENLV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.05 | 25.51M | 0 | -14.33M | -13.21M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-02 | 繰り返されました | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd (ENLV) 最新ニュース
Will Enlivex Therapeutics Ltd. stock maintain dividend yield2025 Short Interest & Low Drawdown Investment Strategies - newser.com
Can Enlivex Therapeutics Ltd. stock maintain operating margins2025 Top Decliners & Safe Capital Growth Tips - newser.com
Why analysts remain bullish on Enlivex Therapeutics Ltd. stockBull Run & Stock Timing and Entry Methods - newser.com
Will Enlivex Therapeutics Ltd. stock gain from strong economyQuarterly Risk Review & Free Expert Approved Momentum Trade Ideas - newser.com
Trend analysis for Enlivex Therapeutics Ltd. this weekTrade Exit Summary & Community Consensus Trade Signals - newser.com
Has Enlivex Therapeutics Ltd. found a price floorTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
Technical signs of recovery in Enlivex Therapeutics Ltd.2025 Risk Factors & AI Enhanced Trade Execution Alerts - newser.com
Can Enlivex Therapeutics Ltd. stock deliver consistent earnings growthQuarterly Performance Summary & Technical Pattern Based Signals - newser.com
What’s the recovery path for long term holders of Enlivex Therapeutics Ltd.July 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Will Enlivex Therapeutics Ltd. stock deliver shareholder valueQuarterly Trade Report & High Accuracy Swing Trade Signals - newser.com
Comparing Enlivex Therapeutics Ltd. in custom built stock radarsJuly 2025 Movers & Real-Time Volume Analysis Alerts - newser.com
How Enlivex Therapeutics Ltd. stock reacts to job market dataDividend Hike & Low Risk Investment Opportunities - newser.com
Why Enlivex Therapeutics Ltd. stock is considered a top pickMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
How to recover losses in Enlivex Therapeutics Ltd. stock2025 Retail Activity & Weekly High Momentum Picks - newser.com
Published on: 2025-10-31 00:58:35 - newser.com
Published on: 2025-10-30 23:36:56 - newser.com
Backtesting results for Enlivex Therapeutics Ltd. trading strategiesQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Using portfolio simulators with Enlivex Therapeutics Ltd. includedEarnings Recap Summary & AI Enhanced Execution Alerts - newser.com
Price action breakdown for Enlivex Therapeutics Ltd.Weekly Earnings Recap & Real-Time Stock Price Movement Reports - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Times Telegram
D. Boral Capital Maintains Enlivex Therapeutics (ENLV) Buy Recommendation - Nasdaq
ENLV Stock Rating Maintained at 'Buy' by D. Boral Capital | ENLV - GuruFocus
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Shelby Star
Risk Report: How Enlivex Therapeutics Ltd. stock responds to policy changesEarnings Recap Summary & Community Trade Idea Sharing Platform - Fundação Cultural do Pará
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - The Manila Times
Enlivex Therapeutics Ltd. to Present Positive Phase IIa Clinical Data for Allocetra™ at ACR Convergence 2025 - Quiver Quantitative
Enlivex (Nasdaq: ENLV) to present 3-month data; pain and function improvement in knee OA - Stock Titan
Enlivex Therapeutics Ltd (ENLV) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):